Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. reported a 76% year-over-year increase in revenue for Q3 FY25, attributed in large part to the integration of their new SCN model, which is anticipated to facilitate accelerated market adoption and revenue growth with minimal additional investment. The company's service revenue exceeded $4.6 million, with key contributions from sleep testing and treatment-center revenue, reinforcing the efficacy of the Vivos System, where significant improvements were observed in patients with moderate to severe obstructive sleep apnea. With the North American market currently leading and rapid growth expected in the Asia Pacific region, Vivos Therapeutics is well-positioned for continued revenue growth and market expansion in the coming quarters.

Vivos Therapeutics Inc. has experienced a year-over-year revenue decline of 9% in 1H25, largely attributed to its transition towards a direct sleep center management model, which has also led to a drop in gross margins to 55% due to discounting practices and alterations in their product and service offerings. The company's financial challenges are compounded by an ongoing record of operating losses, negative cash flow, and a substantial accumulated deficit, raising concerns over its ability to achieve sustainable profitability and growth. Additional risks, including lower-than-expected sales growth, difficulty in securing capital, and challenges in customer acquisition, contribute to an overall negative outlook on the company’s financial stability.